Literature DB >> 2203830

Malignant, non-Hodgkin's lymphomas in Trypanosoma cruzi-infected rabbits treated with nitroarenes.

A R Teixeira1, R Silva, E Cunha Neto, J M Santana, L V Rizzo.   

Abstract

Use of 2-nitroimidazole, 5-nitrofuran and 5-nitroimidazole compounds in T. cruzi-infected rabbits resulted in a reduction in duration of parasitaemia in comparison with untreated, infected rabbits. The chronic myocarditis associated with Chagas' disease was not, however, prevented in nitroarene-treated rabbits; lymphocytic infiltrates associated with cardiac cell lysis, in the absence of parasites in situ, were present in both treated and untreated rabbits. The carcinogenic effect of each trypanocidal nitroarene used in this study was also assessed. Administration of nitroarenes to rabbits resulted in the appearance of solid tumours in 37.8 per cent of animals that received drug therapy. Untreated, control rabbits in this series did not show tumour growth. Furthermore, malignant, mixed-cell type, non-Hodgkin's lymphomas were seen in 32.4 per cent of the treated rabbits. It seems that a direct relationship could be present between the presence of the nitro group, the trypanocidal cytotoxicity and the prevalence of tumours. Benznidazole cleared up parasitaemias in the shortest time and was associated with 41.6 per cent of lymphoma growths, whereas MK-436 required twice as much time to clear blood parasites, and showed lymphomas in 25 per cent of experimental rabbits. The demonstration of a high prevalence of malignant tumours in addition to the chronic myocarditis of Chagas' disease in nitroarene-treated rabbits is important since indiscriminate use of such compounds currently used to treat T. cruzi infections in man could increase the risk of lymphoma.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2203830     DOI: 10.1016/s0021-9975(08)80133-8

Source DB:  PubMed          Journal:  J Comp Pathol        ISSN: 0021-9975            Impact factor:   1.311


  6 in total

Review 1.  Pathogenesis of chagas' disease: parasite persistence and autoimmunity.

Authors:  Antonio R L Teixeira; Mariana M Hecht; Maria C Guimaro; Alessandro O Sousa; Nadjar Nitz
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

2.  Genotoxicity revaluation of three commercial nitroheterocyclic drugs: nifurtimox, benznidazole, and metronidazole.

Authors:  Annamaria Buschini; Lisa Ferrarini; Susanna Franzoni; Serena Galati; Mirca Lazzaretti; Francesca Mussi; Cristina Northfleet de Albuquerque; Tânia Maria Araújo Domingues Zucchi; Paola Poli
Journal:  J Parasitol Res       Date:  2009-10-21

Review 3.  Human antiprotozoal therapy: past, present, and future.

Authors:  M Khaw; C B Panosian
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

Review 4.  Chagas' disease.

Authors:  H B Tanowitz; L V Kirchhoff; D Simon; S A Morris; L M Weiss; M Wittner
Journal:  Clin Microbiol Rev       Date:  1992-10       Impact factor: 26.132

5.  Therapy of chagas disease: implications for levels of prevention.

Authors:  Sergio Sosa-Estani; Lisandro Colantonio; Elsa Leonor Segura
Journal:  J Trop Med       Date:  2012-03-05

6.  Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States.

Authors:  Colin J Forsyth; Salvador Hernandez; Wilman Olmedo; Adieb Abuhamidah; Mahmoud I Traina; Daniel R Sanchez; Jonathan Soverow; Sheba K Meymandi
Journal:  Clin Infect Dis       Date:  2016-07-17       Impact factor: 9.079

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.